BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 20123207)

  • 21. Transjugular intrahepatic portosystemic shunt: efficacy for the treatment of portal hypertension and impact on liver transplantation.
    Cosenza CA; Hoffman AL; Friedman ML; Sher LS; Lopez RR; Van Allen R; Brown DH; Fraiman MH; Arnaout W; Vierling J; Makowka L
    Am Surg; 1996 Oct; 62(10):835-9. PubMed ID: 8813166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transjugular intrahepatic portosystemic shunt migration in patients undergoing liver transplantation.
    Khan TT; Reddy KS; Johnston TD; Lo FK; Shedlofsky S; Grubb S; Ranjan D
    Int Surg; 2002; 87(4):279-81. PubMed ID: 12575815
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Patency and Clinical Analysis of Expanded Polytetrafluoroethylene-Covered Transjugular Intrahepatic Portosystemic Shunt Stent Grafts.
    Weber CN; Nadolski GJ; White SB; Clark TW; Mondschein JI; Stavropoulos SW; Shlansky-Goldberg RD; Trerotola SO; Soulen MC
    J Vasc Interv Radiol; 2015 Sep; 26(9):1257-65; quiz 1265. PubMed ID: 25990133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality.
    Russo MW; Sood A; Jacobson IM; Brown RS
    Am J Gastroenterol; 2003 Nov; 98(11):2521-7. PubMed ID: 14638358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension.
    Colombato L
    J Clin Gastroenterol; 2007; 41 Suppl 3():S344-51. PubMed ID: 17975487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transjugular intrahepatic portosystemic shunt following liver transplantation: can outcomes be predicted?
    El Atrache M; Abouljoud M; Sharma S; Abbass AA; Yoshida A; Kim D; Kazimi M; Moonka D; Brown K
    Clin Transplant; 2012; 26(4):657-61. PubMed ID: 22309034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transjugular intrahepatic portosystemic shunt (TIPS) in patients with refractory ascites: effect on body weight and Child-Pugh score.
    Trotter JF; Suhocki PV; Rockey DC
    Am J Gastroenterol; 1998 Oct; 93(10):1891-4. PubMed ID: 9772050
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of transjugular intrahepatic portosystemic shunt through the left branch vs. the right branch of the portal vein in advanced cirrhosis: a randomized trial.
    Chen L; Xiao T; Chen W; Long Q; Li R; Fang D; Wang R
    Liver Int; 2009 Aug; 29(7):1101-9. PubMed ID: 19386025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic capability of different liver disease scoring systems for prediction of early mortality after transjugular intrahepatic portosystemic shunt creation.
    Gaba RC; Couture PM; Bui JT; Knuttinen MG; Walzer NM; Kallwitz ER; Berkes JL; Cotler SJ
    J Vasc Interv Radiol; 2013 Mar; 24(3):411-20, 420.e1-4; quiz 421. PubMed ID: 23312989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cirrhotic patients with a transjugular intrahepatic portosystemic shunt undergoing major extrahepatic surgery.
    Kim JJ; Dasika NL; Yu E; Fontana RJ
    J Clin Gastroenterol; 2009 Jul; 43(6):574-9. PubMed ID: 19169145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MELD score less than 15 predicts prolonged survival after transjugular intrahepatic portosystemic shunt for refractory ascites after liver transplantation.
    Feyssa E; Ortiz J; Grewal K; Azhar A; Parsikia A; Tufail K; Hashemi N; Brady P; Araya V
    Transplantation; 2011 Apr; 91(7):786-92. PubMed ID: 21304440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of transjugular intrahepatic portosystemic shunt induced refractory hepatic encephalopathy with the parallel technique: results of a clinical follow-up study.
    Maleux G; Heye S; Verslype C; Nevens F
    J Vasc Interv Radiol; 2007 Aug; 18(8):986-92; quiz 993. PubMed ID: 17675616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TIPS for refractory ascites: a 6-year single-center experience with expanded polytetrafluoroethylene-covered stent-grafts.
    Bercu ZL; Fischman AM; Kim E; Nowakowski FS; Patel RS; Schiano TD; Chang CY; Lookstein RA
    AJR Am J Roentgenol; 2015 Mar; 204(3):654-61. PubMed ID: 25714299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transjugular intrahepatic portosystemic shunts for refractory ascites after liver transplantation.
    Abouljoud M; Yoshida A; Kim D; Jerius J; Arenas J; Raoufi M; Brown K; Moonka D
    Transplant Proc; 2005 Mar; 37(2):1248-50. PubMed ID: 15848685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Older patient age may predict early mortality after transjugular intrahepatic portosystemic shunt creation in individuals at intermediate risk.
    Parvinian A; Shah KD; Couture PM; Minocha J; Knuttinen MG; Bui JT; Gaba RC
    J Vasc Interv Radiol; 2013 Jul; 24(7):941-6. PubMed ID: 23707226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites.
    Rössle M; Ochs A; Gülberg V; Siegerstetter V; Holl J; Deibert P; Olschewski M; Reiser M; Gerbes AL
    N Engl J Med; 2000 Jun; 342(23):1701-7. PubMed ID: 10841872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of clinical response to transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients with refractory ascites.
    Deschênes M; Dufresne MP; Bui B; Fenyves D; Spahr L; Roy L; Lafortune M; Pomier-Layrargues G
    Am J Gastroenterol; 1999 May; 94(5):1361-5. PubMed ID: 10235219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis.
    Ginès P; Uriz J; Calahorra B; Garcia-Tsao G; Kamath PS; Del Arbol LR; Planas R; Bosch J; Arroyo V; Rodés J
    Gastroenterology; 2002 Dec; 123(6):1839-47. PubMed ID: 12454841
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MELD score as a predictor of early death in patients undergoing elective transjugular intrahepatic portosystemic shunt (TIPS) procedures.
    Montgomery A; Ferral H; Vasan R; Postoak DW
    Cardiovasc Intervent Radiol; 2005; 28(3):307-12. PubMed ID: 15886944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Model for End-Stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients.
    Hayashi PH; Forman L; Steinberg T; Bak T; Wachs M; Kugelmas M; Everson GT; Kam I; Trotter JF
    Liver Transpl; 2003 Jul; 9(7):737-40. PubMed ID: 12827562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.